Lucid Diagnostics, Subsidiary of PAVmed, Secures Medicare Reimbursement and Closes $15 Million Financing

Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., has begun receiving Medicare reimbursement for its EsoGuard® Esophageal DNA Test, which is expected to enhance its engagement with large health systems and aid in obtaining broader commercial payor coverage. Additionally, the company completed a $15 million private placement of Series C Convertible Preferred Stock with existing long-term shareholders. These developments are significant for PAVmed, providing both capital and operational momentum.